CML: genetic paradigm of targeted therapy 1

Published on September 30, 2015   24 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Cancer Genetics

MICHAEL DEININGER: Hello, I'm Michael Deininger. I'm the chief of the Division of Hematology and Hematologic Malignancies at the University of Utah, Huntsman Cancer Institute. Today, we're going to talk about chronic myeloid leukemia, or CML, genetic paradigm of targeted therapy. The first part of the presentation will focus on the biology of CML, the Philadelphia chromosome, and the development of Imatinib as the first targeted agent tyrosine kinase inhibitor for CML.
The story of chronic myeloid leukemia, or CML, starts in the middle of the 19th century. There were three eminent physicians making major contributions. Alfred Donné, in Paris, was probably the first to recognize leukemia also under the microscope. John Bennet, in Edinburgh, was the first to see a case of CML and describe it. Bennet thought that the case was actually due to an infection, because there was a 'separation of the spleen', as he called it. And just a few weeks later, Rudolf Virchow, in Berlin, described a similar case, but he recognized the neoplastic nature of the disease.

CML: genetic paradigm of targeted therapy 1

Embed in course/own notes